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Ventricular–arterial coupling in cardiac disease 403
Ventricular–arterial coupling (VAC) plays a major role in the physiology of cardiac and aortic mechanics, as well as in the pathophysiology
of cardiac disease. VAC assessment possesses independent diagnostic and prognostic value and may be used to refine riskstratification and
monitor therapeutic interventions. Traditionally, VAC is assessed by the non-invasive measurement of the ratio of arterial (Ea) to ventricular
end-systolic elastance (Ees). With disease progression, both Ea and Ees may become abnormal and the Ea/Ees ratio may approximate
its normal values. Therefore, the measurement of each component of this ratio or of novel more sensitive markers of myocardial (e.g.
global longitudinal strain) and arterial function (e.g. pulse wave velocity) may better characterize VAC. In valvular heart disease, systemic
arterial compliance and valvulo–arterial impedance have an established diagnostic and prognostic value and may monitor the effects of
valve replacement on vascular and cardiac function. Treatment guided to improve VAC through improvement of both or each one of its
components may delay incidence of heart failure and possibly improve prognosis in heart failure. In this consensus document, we describe
the pathophysiology, the methods of assessment as well as the clinical implications of VAC in cardiac diseases and heart failure. Finally, we
focus on interventions that may improve VAC and thus modify prognosis.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Keywords Ventricular–arterial coupling • Arterial elastance • Ventricular elastance • Global longitudinal strain •
Pulse wave velocity • Valvular heart disease • Hypertension • Inflammatory disease •
Coronary artery disease • Heart failure • Prognosis • Treatment
Introduction
The important role of ventricular–arterial coupling (VAC) in the
physiology of cardiac and aortic mechanics, as well as in the patho-
physiology of cardiac disease has long been recognized. Despite
its complexity, several invasive and non-invasive methods have
been developed to measure VAC. In this consensus document, we
describe the pathophysiology of VAC impairment and the mech-
anisms that can affect arterial and cardiac function and their rela-
tion. Traditional VAC assessment methods are presented, together
with novel approaches. Furthermore, we analyse the clinical impli-
cations of VAC in arterial hypertension, systemic inflammatory
diseases, coronary artery disease (CAD), valvular heart disease,
and heart failure (HF). Finally, we focus on invasive and non-invasive
interventions that may improve VAC.
Pathophysiology
of ventricular–arterial coupling
Heart–vessel coupling is constantly changing to match ventricular
end-systolic and arterial elastances, a concept that finds its origins
in the pressure–volume (P-V) cardiac function analysis as assessed
by cardiac catheterization.1 By connecting all end-systolic points
of a family of P-V loops obtained during various loading conditions,
the so-called ‘end-systolic pressure–volume relation’ (ESPVR) line
is retrieved (Figure 1A).1 Suga and Sagawa1 found this relation to
be roughly linear within physiologic ranges, sensitive to inotropic
changes, and insensitive to afterload, while the respective line slope
has been termed as end-systolic elastance (Ees). Conceptualising
the left ventricle as a closed volume, Ees represents the necessary
intracavitary pressure to increase its volume by one unit.1 The
intersection between the ESPVR (upper left-hand corner of the
P-V loop) and a line drawn from the end-diastolic volume on the
horizontal axis identifies a second line. The respective slope repre-
sents the end-systolic pressure to stroke volume (SV) ratio, termed















































































Figure 1 (A) Left ventricular (LV) end-systolic elastance (Ees)
estimated by pressure–volume loop family, end-systolic point
line. By connecting all end-systolic points of pressure–volume
loops obtained during various loading conditions, the so-called
‘end-systolic pressure–volume relation’ (ESPVR) line is retrieved.
(B) LV Ees estimated as the end-systolic pressure/end-systolic
stroke volume ratio and arterial elastance (Ea) estimated as the
end-systolic pressure/stroke volume ratio are used to calculate
Ea/Ees ratio as a marker of ventricular–arterial coupling using a
single pressure volume loop.
based on mechanoenergetic grounds, that stroke work generation
is maximal when the Ea/Ees ratio equals 1, while maximal cardiac
efficiency is achieved when the Ea/Ees ratio equals 0.5.2
Ventricular–arterial stiffening amplifies the elevation of blood
pressure (BP) induced by exercise or mental stress and this may
further worsen left ventricular (LV) diastolic function and increase
cardiac energy costs to provide an adequate output.3 This may
exacerbate the effect of the systemic load on LV diastolic func-
tion and elevate cardiac metabolic demand, as well as LV diastolic
filling pressures under stress causing HF symptoms, further com-
promising myocardial reserve in the long term.3,4
Although the P-V analysis (Figure 1B) provides useful information
regarding the operating mechanical efficiency and performance of
the ventricular–arterial system when LV ejection fraction is frankly
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Figure 2 Vascular mechanisms that lead to impaired left ventricular (LV) function. Aix, augmentation index; PWV, pulse wave velocity; SNS,
sympathetic nervous system; SV, stroke volume.
abnormal, it is less informative in HF with preserved ejection
fraction (HFpEF), as discussed later.
Effects of arterial function on left
ventricular structure and performance
The heart ejection generates forward pressure and flow waves,
transmitted down the arterial tree, giving rise to reflections which,
in a stiffened aorta, arrive early in systole instead of diastole and,
thus, increase central systolic BP and reduce diastolic BP, a key
determinant of the coronary perfusion gradient.4 The increase in
afterload increases myocardial oxygen demand, and the reduction
in coronary perfusion pressure decreases oxygen delivery creat-
ing conditions of myocardial ischaemia, further deteriorating LV
systolic and diastolic performance (especially during exercise).4
Furthermore, reflected waves increase late systolic load rela-
tive to early systolic load, which has deleterious effects on the
myocardium.
In general, arterial load can be expressed as the combination of
steady and various pulsatile components. The steady component
of afterload (i.e. total peripheral resistance) depends largely on
microvascular properties. Pulsatile LV afterload is, in contrast,
predominantly influenced by the properties of conduit vessels.
Key parameters of pulsatile LV load include the characteristic
impedance of the proximal aorta (Zc), the magnitude and timing
of wave reflections, and the total compliance of the arterial tree
(‘total arterial compliance’) (for definitions see section ‘Markers of
arterial function’).
Arterial load (arterial compliance, total vascular resistance












































. stiffness [pulse wave velocity (PWV)] are closely related with LV
diastolic function, LV mass, and myocardial deformation [e.g. global
longitudinal strain (GLS)].5–8 In fact, LV diastolic dysfunction, LV
hypertrophy, abnormal myocardial deformation, and increased aor-
tic stiffness share many epidemiological and pathophysiological fea-
tures: they predominate in elderly subjects and hypertensives, have
a predictive value for morbidity and mortality, and share under-
lying biochemical mechanisms of remodelling (collagen deposi-
tion, increased cellular stiffness, production of advanced glycation
end-products in diabetes mellitus). Furthermore, impairment of
coronary flow reserve is associated with increased arterial stiffness
and myocardial dysfunction in hypertension, inflammatory diseases,
and CAD.6
Carotid to femoral PWV (cfPWV), aortic characteristic
impedance (Zc), and the magnitude and timing of wave reflec-
tions during systole summate the impact of arterial load on LV
function at systole and diastole7 that triggers the onset of clin-
ical symptoms,8 and contributes to cardiovascular events.9 The
vascular mechanisms that may lead to an impaired LV function
are summarized in Figures 2 and 3. Increased arterial stiffness
(as measured by PWV) results in faster pulse wave propagation,
earlier reflection and arrival of backward pulse waves during late
systole, instead of diastole; thus, early arrival in systole augments
central aortic pressure and thus LV afterload and myocardial
oxygen demand, and lowers central diastolic arterial pressure
and thus coronary perfusion and myocardial oxygen delivery. The
imbalance between increased myocardial oxygen demands and
reduced coronary perfusion leads to myocardial ischaemia in the
absence of coronary stenosis (Figure 3).
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Figure 3 Effects of increased arterial stiffness and the concomi-
tant earlier arrival of wave reflections from the peripheral arteries
on central aortic pressure waveform. The pulse wave with blue
line indicates augmentation of aortic pressure in diastole by return
wave reflections under conditions of normal arterial elastic prop-
erties while the aortic systolic component remains unaffected
(blue line). The pulse wave with red line indicates augmentation
of central aortic pressure in systole by the early arrival of wave
reflection (orange line and orange arrow) because of increased
arterial stiffness and reduced central diastolic pressure compared
to diastolic pressure during the normal (diastolic) arrival of wave
reflection (blue line) when arterial elasticity is not impaired. DBP,
diastolic blood pressure; LV, left ventricular; PP, pulse pressure;
SBP, systolic blood pressure.
Effects of cardiac function on arterial
properties
The left ventricle, aortic valve, aorta, and peripheral arteries
should be regarded as interdependent organs placed in a series
circuit. The principles of complementarity (all compartments
contribute additively to afterload) and competitiveness (one com-
partment cannot be lowered without raising the other one) reflect
their interdependence and the common physiological mechanisms
that coordinate their function.10 During systole, a pulse wave is
propagated along the aorta to the periphery stretching the arterial
wall. Moreover, capacitance vessels distend to accommodate the
increased LV SV during exercise. Furthermore, LV SV reduction
does lead to neurohumoral and sympathetic activation, also
contributing to vascular dysfunction.
Common biochemical pathways
determining arterial and cardiac function
Extracellular matrix and cytoskeleton regulation processes are bio-
chemical pathways that concomitantly affect cardiac and arterial
structure and function through replacement or reactive fibrosis.
Transforming growth factor-𝛽 serves as a biochemical coordina-
tor, activating fibroblasts and myofibroblasts. The fibroblast plays
a key role in inflammation, proliferation/apoptosis, angiogenesis
(induced by growth factors) and upon stimulation by angiotensin
II it produces collagen.11 Under normal conditions, a balance



















































































.. Degradation is the task of matrix metalloproteinases. In the pres-
ence of disease or with aging, extracellular matrix synthesis grad-
ually predominates, setting the stage for accelerated fibrosis.12,13
High galectin-3 levels, a marker of myocardial and vascular fibrosis,
predicted impaired VAC.13
Endothelial-derived nitric oxide, cytokines, oxidative stress
proteins and growth factors determine myocardial microcircu-
latory function, as well as aortic and peripheral vasoreactivity.14
Moreover, neurohumoral factors including adipokines, leptin,
and sex hormones have also been implicated in the process
of ventricular–arterial decoupling by affecting LV hypertrophy,
vascular wall hypertrophy, and vasoconstriction.15,16 For example,
ventricular–arterial decoupling was associated with impaired LV
performance and was attributed to inflammation in septic shock.17
The above mechanisms act in parallel to modify arterial and cardiac
function in adaptive or maladaptive ways.
Key points
• Reflected waves, which arrive in late systole, increase
end-systolic stress and impair diastolic function.
• Changes in LV SV affect vascular function.
• Fibrosis, inflammation and oxidative stress are common




Although VAC is most frequently assessed in the P-V plane by cardiac
catheterization, this approach has important limitations (Table 1).2
Currently, the most widely used echocardiographic method for the
determination of Ea/Ees (normal value 1.0± 0.36) is the single-beat
method developed by Chen et al.18 Although several methods are
available, it remains unclear which provides the most reliable results.
According to this method, Ees can be calculated non-invasively by the
formula:
Ees = (DBP– [End (est) × SBP × 0.9)] ∕End (est) × SV
(normal value ∶ 2.3 ± 1.0mmHg∕mL)
where DBP and SBP are diastolic and systolic arm-cuff BPs, End(est) is
the estimated normalized ventricular elastance at the onset of ejection,
and SV is Doppler-derived stroke volume. End(est) is described by the
following formula:
End (est) = 0.0275 − 0.165 × EF + 0.3656
× (DBP∕SBP × 0.9) + 0.515 × End (avg)
where EF is the basal ejection fraction and End(avg) is derived by a
complicated formula:
End (avg) = 0.35695 − 7.2266 × tNd + 74.249 × tNd2 − 307.39
× tNd3 + 684.54 × tNd4 –856.92 × tNd5
+ 571.95 × tNd6 − 159.1 × tNd7
where tNd is the ratio of pre-ejection period to total systolic
period.
© 2019 The Authors
European Journal of Heart Failure © 2019 European Society of Cardiology
406 I. Ikonomidis et al.
We note that this polynomial formula uses the ratio of pre-ejection
period to total systolic period raised to multiple powers (up to the sev-
enth) such that small variations or errors in the measurements of time
intervals will lead to relatively large changes in the estimated Ees value.
Effective arterial elastance (Ea) can be computed using the following
formula3:
Ea = (SBP × 0.9) ∕SV (normal value ∶ 2.2 ± 0.8mmHg∕mL) .
However, a simplified formula frequently used to assess VAC is the
following:
Ea = ESP∕SV, Ees = ESP∕ESV
where ESP is end-systolic pressure, SV is stroke volume, and ESV is
end-systolic volume. Thus, Ea/Ees= (ESP/SV)/(ESP/ESV) and then by
eliminating ESP:
Ea∕Ees = ESV∕SV,which equals to 1∕ (EF − 1) .
It becomes readily apparent that the advantage of the Ea/Ees ratio as
a method to provide additional insights about the physiologic status of
the ventricular–arterial system is blunted, as it becomes a derivative of
LV ejection fraction. Thus, the full formula by Chen et al.18 should be
used to calculate Ees and then to be divided to Ea in order to obtain
an Ea/Ees ratio that accurately reflects invasive Ea/Ees measures.
Three-dimensional echocardiography or magnetic resonance imag-
ing measure LV volumes more accurately than two-dimensional
echocardiography and should be preferred for the calculation of
LV (or right ventricular) volumes included in the aforementioned
VAC estimation formulas.19 Finally, in several cardiac diseases (e.g.
hypertension, inflammatory diseases, or diabetes), the components
Ea and Ees may be similarly impaired, providing an Ea/Ees ratio of
around 1; therefore, the extent of physiologic abnormalities should be
assessed by the absolute value of each component.2 The advantages
and disadvantages, as described in Table 1, pertain to both invasive
and non-invasive determinations of the Ea/Ees ratio. However, we
should acknowledge that cardiac catheterization provides more accu-
rate measurement of Ea and Ees than non-invasive methods while
non-invasive methods are applicable for repeated consecutive studies
of VAC, e.g. before and after treatment in daily clinical practice. Thus,
we propose the simultaneous measurement of arterial and novel
myocardial function markers, as described above, that may provide a
more accurate estimation of VAC and its changes in disease or after
treatment.
Markers of arterial function
Arterial load depends on the properties of small and large arteries.
Indices of the properties of large vessels include aortic characteris-
tic impedance (Zc), aortic distensibility, beta stiffness index, and large
artery stiffness (estimated by aortic PWV) (Table 1). Finally, other
indices ‘blend’ the effect of small and large arteries, such as central
systolic BP and pulse pressure, indices of wave reflections (e.g. augmen-
tation index), brachial–ankle PWV, and total arterial compliance.20
Regional arterial wall properties
Characteristic impedance of the proximal aorta (Zc) can be intu-
itively measured as the slope of the pulsatile pressure–flow relation
(where pressure and flow are measured in the same point within
the artery) in the absence of reflected waves (Figure 4A–E). It is a



















































































.. effects and the local storage of blood in the proximal aorta and the
load initially experienced by the ventricle upon opening of the aor-
tic valve. It can be measured non-invasively. Two-dimensional guided
mode echocardiography of the aortic root to assess aortic root diam-
eter changes between systole (AoS) and diastole (AoD) combined
with simultaneous sphygmomanometric measurements of the arterial
pressure (PP) at the brachial artery has been used to assess aortic
distensibility (2× (AoS−AoD)/(AoD× PP),21 though this index was
initially measured invasively. A stiff and narrow aorta leads to high Zc
and low aortic distensibility, whereas a distensible, wide aorta to a
low Zc and increased aortic distensibility. The local stiffness param-
eter beta can also be calculated according to the formula Beta= ln
(Ps/Pd)/(Ds−Dd/Dd), where Ps and Pd are systolic and diastolic BP
in the brachial artery measured by an automated sphygmomanometer,
and Ds and Dd are the maximal and minimal diameters of the right
common carotid artery measured by ultrasonic high resolution wall
tracking22 or of the aorta by echocardiography.21
Large artery stiffness
Carotid to femoral PWV, which is the velocity of the pulse as it travels
from the heart to the carotid and femoral artery, remains the most
commonly used non-invasive method and is considered as the ‘gold
standard’. cfPWV is usually measured using surface tonometry probes
at the right common carotid and right femoral artery. The transit time
is the time of travel of the wave over these sites. The distance (D)
covered by the waves is usually assimilated to the skin distance between
these two recording sites; PWV is calculated as PWV=D/Dt (m/s).20
Brachial–ankle PWV capitalizes on the concept that measurements
over a longer arterial length may provide additional information.20
Central haemodynamics/wave reflections
Pressure and flow waves are generated with each heartbeat and are
propagated towards the periphery where they are reflected back-
wards, merge with the antegrade wave and amplify it. As a result,
peripheral BPs are higher compared to central (aortic) BPs. Central
BPs are more relevant than peripheral ones, as the heart, brain
and kidneys are directly exposed to them. Central haemodynamic
indices are either central BP parameters and derivatives (central
systolic BP, pulse pressure, augmented pressure and amplification),
or indices that quantify timing and magnitude of wave reflections
(obtained by pulse wave analysis in the frequency domain and wave
separation analysis). A frequently used central augmentation index
is measured non-invasively by arterial tonometry and is calculated
as 100× peak central systolic BP/central pressure at the inflection
point and represents the pressure boost that is induced by the return
of the reflected waves at the aorta.20 Central pulse wave recordings
are obtained by cardiac catheterization or non-invasively by arterial
tonometry or oscillometry devices (Figure 4A). Furthermore, the
newly developed techniques of pressure–flow (Figure 4A–E) and
wave separation analysis (Figure 4F–G) may offer more insight into
the assessment of vascular haemodynamics in various disease states
by measurement of both forward and backward compression and
expansion pulse wave. Wave reflection assessment by wave separation
analysis is based on the principle that reflected waves add to forward
pressure and subtract from forward flow distorting the linear relation-
ship between the increase in pressure and the increase in flow that
is seen in early systole when the pulsatile pressure–flow relation is
governed by aortic root Zc (Figure 4E and G). Several lines of evidence
support the importance of late systolic load from wave reflections
© 2019 The Authors
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Ea/Ees • Widely used with extensive published data
• Relatively simple and intuitive
• Characterizes mechanical indices that relate to
energetics (only when EF<∼40%):
• External mechanical energy
• Potential energy
• Energetic efficiency
• Allows us to discern the determinants of stroke
volume and EF
• Cardiac catheterization for pressure–volume loops
• Echocardiography provides an approximation of
Ea/Ees and its components
Disadvantages of Ea:
• It is not a pure index of arterial load because it is
prominently influenced by heart rate
• It is mostly dependent on resistance and is insensitive
to changes in pulsatile arterial load
• It is not a measure of arterial stiffness or total arterial
compliance
• Its derivation did not account for wave reflection or
transmission
• It does not discern the temporal pattern of load
(loading sequence) which is an important
determinant of diastolic dysfunction, maladaptive LV
remodelling and heart failure risk
Disadvantages of Ees:
• Non-linearity of the ESPVR
• It demonstrates afterload dependency
• It demonstrates some preload dependency
• It does not assess myocardial properties (only
‘chamber’ properties)
• Little validation of single-beat non-invasive methods
beyond the original derivation study
Disadvantages of Ea/Ees:
• It does not characterize (and neglects) LV loading
sequence
• In HFpEF, it may be normal because both Ea and Ees
are increased
• Ea/Ees derived by the simplified formula (ESV/SV
ratio) is related mathematically to EF (1/EF – 1) and
thus may not add substantial information to EF
measurement
Arterial stiffness markers
Total arterial compliance • Assessment of the compliance of the whole arterial
tree
• Measured non-invasively
• Depends non-linearly on arterial pressure
• It is size-dependent
• There are systematic differences between different
methods, making it difficult to standardize
• Required expertise is high
• Limited prognostic and therapeutic data
Pulse wave velocity • Solid pathophysiological background
• Can be measured non-invasively in a standardized
manner at a low cost, requiring low expertise
• Significant prognostic and therapeutic data
• Reference values established
• It depends on arterial pressure






• Solid pathophysiological background
• Can be measured non-invasively
• Prognostic data are available
• Reference values established
• Estimations are based on assumptions and
algorithms
• More prognostic and therapeutic data are needed
© 2019 The Authors
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• Solid pathophysiological background
• It can be measured non-invasively
• It is dependent on blood pressure and aortic size
• Increased cost for the equipment
• Significant expertise needed for its estimation
• Limited prognostic and therapeutic data
Valvulo–arterial
impedance (Zva)
• Solid pathophysiological background
• It can be measured non-invasively
• Prognostic data are available
• Reference values are available
• It is dependent on blood pressure and loading
conditions
• Technical limitations of Doppler echocardiographic





• High temporal resolution
• Wealth of published data
• Beam orientation frequently off axis
• Single dimension, i.e. representative only in
normally shaped ventricles
2D • Facilitates orientation perpendicular to the ventricular long
axis
• Lower frame rates than M-mode
• Single dimension, i.e. representative only in
normally shaped ventricles
Volume assessment
2D • Corrects for shape distortions
• Less geometrical assumptions compared with linear
dimensions
• Apex frequently foreshortened
• Endocardial dropout
• Blind to shape distortions not visualized in the
apical two- and four-chamber planes
3D • No geometrical assumption
• Unaffected by foreshortening
• More accurate and reproducible compared to other
imaging modalities
• Lower temporal resolution
• Less published data on normal values




• High temporal resolution
• Established prognostic value of E’,S’ and E/E’
• Incorporated in all echo systems
• Reference values established
• Angle-dependent, affected by noise
• Assessment of longitudinal and radial deformation
• Time consuming for strain analysis
• Moderate reproducibility/inter and intra-observer




• Assessment of longitudinal, radial and circumferential
deformation
• Assessment of LV twisting–untwisting properties
• Established prognostic value for GLS
• RV assessment
• Pressure–strain loops to assess myocardial work index
• Good reproducibility/inter and intra-observer variability
• 3D imaging is available
• Normal values available
• Vendor dependent
• Dependent on good 2D image quality
• Limited studies on clinical value of 3D strain and
myocardial work index by 2D strain
Time-resolved wall
stress curve
• Calculation using a central pressure waveform derived
non-invasively and time-resolved LV geometric information
derived from echocardiography or cine MRI
characterization of the myocardial loading sequence
• Limited studies on clinical value
PWV to GLS ratio • Established prognostic value for PWV and GLS
• Sensitive markers of arterial and myocardial function
• Limited studies on clinical value in hypertensives
2D, two dimensional; 3D, three dimensional; Aix, augmentation index; Ea, arterial elastance; Ees, left ventricular elastance; EF, ejection fraction; ESPVR, end-systolic
pressure–volume relation; ESV, end-systolic volume; GLS, global longitudinal strain; LV, left ventricular; MRI, magnetic resonance imaging; PWV, pulse wave velocity; RV,
right ventricle; SBP, systolic blood pressure; SV, stroke volume; VAC, ventricular–arterial coupling.
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Figure 4 Legend on next page.
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Figure 4 Analyses of central pressure–flow relations and myocardial wall stress. (A) Arterial tonometry recording. (B) Pulsed wave Doppler
flow velocity recording of the left ventricular outflow tract; this velocity envelope can be multiplied by the left ventricular outflow tract
cross-sectional area to obtain volume outflow from the left ventricle, which equals aortic inflow. (C and D) Signal-averaged pressure and
flow waveforms. (E) Pressure–flow loop showing the linear early systolic pressure–flow relation (green segment); the slope of this line
approximates the aortic characteristic impedance (Zc), which equals the ratio of pulsatile pressure/pulsatile flow in the aortic root in the
absence of wave reflections; a deviation (upward shift) from this linear relation occurs upon the arrival of the reflected wave, which increases
pressure and reduces flow (red segment in the pressure–flow loop). (F) Wave separation analysis which decomposes the pressure waveform
into its forward (Pf) because of left ventricular contraction and backward (Pb) components because of wave reflection at peripheral arterial
sites (e.g. points of branching or change in arterial wall diameter). (G) Measured pressure in systole vs. product of flow time aortic root Zc
(blue area) that denotes the pressure in aortic root during left ventricular systolic contraction if wave reflections were absent; the red area
denotes the ‘excessive’ pulsatile pressure because of the arrival of wave reflections from the peripheral arteries, which is above that required
to ‘accommodate’ observed flow through the aortic root if reflections were absent. The early arrival of wave reflections in systole occurs
when pulse wave velocity is increased because of a stiff aorta; the pink area represents the diastolic component of the central aortic pulse wave
starting after the inflection point that indicates the aortic valve closure (AVC) (arrow). (H) Time-resolved myocardial wall stress in the same
subject, obtained via a combination of arterial tonometry and speckle tracking echocardiography; myocardial wall stress at each time point
during ejection is computed to generate a time-resolved stress curve; notice the early systolic myocardial wall stress peak, with lower values
of wall stress during late systole. (I) Ejection-phase pressure–stress plot showing that the lower wall stress values in late systole are related to
a mid-systolic shift of the pressure–stress relation (green arrow) which favours lower stress values in late systole despite rising pressure. This
mechanism may protect the myocardium against wave reflections, but is impaired in the presence of a low ejection fraction or left ventricular
concentric remodelling, and may be overcome when there is excessive wave reflection magnitude. AVO, aortic valve opening.
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Table 2 Studies presenting the independent value of markers of arterial stiffness as predictors of cardiovascular
events and incident heart failure
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Chirinos et al.9 2012 Primary care population Prospective observational PPA, RM CV mortality and HF incidence 7.6
Aisu et al.24 2017 Risk factors for HF Retrospective observational PWV Hospitalization for new-onset HF 4.9
Chester et al.25 2017 Primary care population Prospective observational RM Incident HF 11.2
Chirinos et al.26 2014 Chronic kidney disease Prospective observational PWV, SBP, PP Hospitalization for new-onset HF 3.5
Ohyama et al.27 2017 Primary care population Prospective observational PWV Incident HF 10
Pandey et al.28 2017 Primary care population Prospective observational PWV Incident HF 11.4
Said et al.29 2018 Primary care population Prospective observational ASI, PP All-cause, CV and non-CV mortality 2.8
Tsao et al.30 2015 Primary care population Prospective observational PWV Incident HF 10.1
Feistritzer et al.87 2017 Acute STEMI Prospective observational PWV MACCE including incident HF 1.2
ASI, arterial stiffness index; CAD, coronary artery disease; CV, cardiovascular; HF, heart failure; MACCE, major adverse cardiac and cerebrovascular events including death,
non-fatal myocardial reinfarction, new-onset congestive HF, and stroke; PP, pulse pressure; PPA, pulse pressure amplification; PWV, pulse wave velocity; RM, reflection magnitude;
SBP, systolic blood pressure; STEMI, ST-elevation myocardial infarction.
as a determinant of maladaptive LV remodelling, diastolic and systolic
dysfunction, and HF risk (Table 2).7–9,12,13
Normal values for PWV (<10/ms) and central systolic BP
(< 130mmHg) have been described23 and their predictive value
for incident cardiovascular mortality and HF has been demonstrated
(Table 2).24–31
Numerous methods have been suggested to estimate total arte-
rial compliance based on the Windkessel (elastic reservoir) model;
most require both accurate pressure and flow wave recording at the
aorta and are hampered by practical and technical (mainly related to
complexity), as well as theoretical limitations (including not account-
ing for wave reflections).20 The SV over pulse pressure method has
been reintroduced recently and it requires accurate and reproducible
echocardiographic measurement of cardiac output; however this ratio
is shown to overestimate compliance and further standardization of
the measurement is required20 (Table 1).
Markers of myocardial performance. Novel echocardiography tech-
niques have permitted the evaluation of myocardial deformation in sys-
tole and diastole by use of tissue Doppler imaging, two-dimensional,
and recently three-dimensional speckle tracking32 (Table 1). Studies
have shown impaired myocardial deformation (e.g. GLS < 20%) in the
presence of normal ejection fraction in patients with hypertension,
diabetes, CAD, valvular heart disease and HF.31,33 Myocardial defor-
mation markers have been related with myocardial fibrosis,34 arterial
stiffness,31,35 natriuretic peptides,8 exercise capacity,36 symptoms of
HF,36 and have a prognostic value in valvular heart disease37 and in HF
with reduced and preserved ejection fraction.2 Thus, these myocardial
deformation markers may be surrogate markers of impaired myocardial
function.
Novel markers to assess ventricular–arterial coupling. Arterial load
should always be interpreted by considering interactions between
arteries and the left ventricle as a pump3,4 and also between myocar-
dial elements and instantaneous LV geometry and the time-varying
load imposed by the systemic circulation. Wall stress represents the




















































. in the myocardium (myocardial afterload) and is related to the amount
of force and work the muscle does during a contraction.
In axisymmetric ventricles, average LV myocardial fibre stress can
easily be approximated by the formula developed by Arts et al.38:








When assuming rotational symmetry and homogeneity of mechan-
ical load in the wall, the dimensionless ratio of muscle fibre stress
[sigma (𝜎) fiber] to LV pressure (P) appears to depend mainly on
the dimensionless ratio of cavity volume (Vlv) to wall volume (Vw) (ln
denotes natural logarithm) and is quite independent of other geometric
parameters.
This method can be applied non-invasively to calculate time-resolved
ejection-phase fibre stress using a central pressure waveform and
time-resolved LV geometric information (derived from echocar-
diography or cine magnetic resonance imaging)2 (Figure 4A–D). A
time-resolved wall stress curve allows for characterization of the
myocardial loading sequence, which can be expressed as a ratio of
the stress-time integral in late vs. early systole. A high late-to-early
systolic stress time integral ratio has been shown to be associated
with reduced indices of myocardial systolic contraction and diastolic
relaxation7,8 and left atrial dysfunction,31 providing a link between
wave reflections and the reported risk of incident HF in the general
population4,9,25 (Figure 4H–I).
New echocardiography software construct arterial pressure–LV
longitudinal myocardial strain curves by speckle tracking echocardio-
graphy and measure the area of the pressure–strain loop, termed
as myocardial work index (Figure 5). The software calculates the
constructive and the wasted myocardial work.39 Further studies are
required to assess the performance of this method for physiologic
and clinical evaluations as this method neglects the work performed
in the circumferential direction. Shear wave generation using an ultra-
sonic burst focused on the myocardium is a novel promising assess-
ment method of myocardial elasticity.40 Finally, the ratio of cfPWV
to LV GLS appears to be a novel promising marker to assess VAC in
hypertensives.41
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Figure 5 Myocardial work index comprises a novel method of ventricular–arterial coupling estimation derived by pressure–left ventricular
longitudinal myocardial strain loop during one cardiac cycle by speckle tracking echocardiography. (A) Before and (B) after cardiac
resynchronization therapy (CRT). Note the larger area of the pressure–strain loop after CRT compared to baseline, indicating an improved
myocardial work during systole after CRT. The bull’s eye shows the myocardial work index in each one of the 17 left ventricular wall segments.
(Echocardiography images provided as courtesy by Dr I. Ikonomidis, Echocardiography Department, Attikon Hospital, NKUA, Athens, Greece).
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In summary, the measurement of novel myocardial and arterial
function markers may be used to describe and quantify VAC in various
disease states.
Key points
• The measurement of novel myocardial and arterial function mark-
ers may describe and quantify VAC, particularly if the traditional
Ea/Ees approximates 1, despite the suspicion or presence of overt
cardiovascular disease (such as in HFpEF).
• Comprehensive assessments of VAC in future studies should
include proper measurements of pulsatile load and VAC (wave
reflections, Zc, wave intensity and wave power analyses), rather
than relying entirely on P-V analyses.
• Other novel markers, such as myocardial work index, may be
informative and compensate for some of the classic method





in hypertension, diabetes, and systemic
diseases
The association between myocardial and arterial function markers
has been used to describe and quantify VAC in hypertension,41,42
diabetes,43 and inflammatory diseases.44,45 More specifically, com-
bined ventricular and arterial stiffening has been demonstrated
in HFpEF patients and hypertensives.3 The investigators found an
inverse correlation between total arterial compliance and Ees,
independently of body surface area and SV. Additionally, both hyper-
tensive and HFpEF patients had reduced Ea/Ees (< 0.6) compared
to healthy controls.3,42
Furthermore, in untreated patients with arterial hypertension,
central augmentation index (measured by arterial tonometry) and
aortic distensibility have been related with abnormal markers of
LV diastolic function as assessed by Doppler echocardiography,45
while PWV has been associated with E/E’ and E’/A’ as assessed by
tissue Doppler imaging.46
Moreover, an interrelation between conduit arterial stiffness and
subendocardial dysfunction as assessed by tissue Doppler imag-
ing in patients with diabetes, hypertension, or ischaemic dilated
cardiomyopathy has been found.22 Additionally, in a study cohort
of hypertensives and diabetics, it has been shown that early dias-
tolic velocity (E’) by tissue Doppler imaging varies inversely with
Zc, Ea, and PWV.6 Late systolic load, as assessed by augmenta-
tion index and arterial compliance, had the strongest association
with E’. Similar associations were found between vascular markers
and systolic mitral annulus velocity (S’).7 In morbidly obese sub-
jects, an inverse relationship between isovolumetric relaxation time
and aortic distensibility (both assessed by echocardiography) was
observed, while weight reduction after bariatric surgery improved



















































































.. In a study including 320 hypertensive patients, increased PWV
was found to be related with abnormal LV longitudinal strain,
reduced LV untwisting and peak untwisting velocity as assessed
by speckle tracking echocardiography.48 In this study, impaired
LV myocardial deformation and untwisting were associated with
reduced exercise capacity.48 Interestingly, increased PWV was
also associated with reduced coronary flow reserve,46 which
in turn was related to abnormal myocardial deformation in
hypertensives.48 A similar association between arterial stiffness
and myocardial deformation was found in chronic kidney disease
patients.49 Similarly, in the context of type 1 diabetes mellitus, a
negative correlation between PWV and left atrial strain has been
underlined.50 Furthermore, in type 2 diabetics, increased PWV
and central aortic pressure were associated with impaired LV
longitudinal deformation and untwisting before and after 6months
of antidiabetic treatment.51
Thus, in hypertension and diabetes there is a close link between
arterial stiffness and myocardial deformation, which appears to be
a harbinger of HFpEF, if left untreated.
Interventions to improve ventricular–arterial coupling
in arterial hypertension
Antihypertensive treatment improved VAC, arterial stiffness,
and LV systolic and diastolic function in 527 patients with early
stage hypertension.52 In the above study, changes in the Ea/Ees
ratio were inversely correlated with those in ejection fraction,
stroke work index, LV efficiency and changes in mitral E/e’. It has
also been shown that improved Ea/Ees after 6months of antihy-
pertensive monotherapy is related with improved LV function and
regression of LV hypertrophy, with angiotensin-converting enzyme
(ACE) inhibitors, angiotensin II receptor blockers (ARBs), and
dihydropyridine calcium antagonists having the most favourable
effect on this index.53
Indeed, the various antihypertensive drug classes have differential
effects on pulsatile and central haemodynamics; ACE inhibitors,
ARBs, calcium-channel blockers, and some vasodilating 𝛽-blockers
are more effective in this regard, compared to diuretics and
some non-vasodilating 𝛽-blockers.54–56ACE inhibitors represent
the first drug class for which a clear advantage over 𝛽-blockers
was demonstrated in terms of effects on central BP, arterial
stiffness and wave reflections. Also ARBs and dihydropyridines
were demonstrated to be able to reduce PWV and improve central
aortic haemodynamics.55,56 Conversely, the majority of studies have
shown that diuretics have a neutral effect on arterial stiffness and
central haemodynamics.
The differential effects of calcium-channel blockers on arte-
rial stiffness may be related to better prognosis as shown by
the CAFÉ-ASCOT study (Table 3).54–56 Evidence showing that an
improvement in wave reflection will lead to a reduction in cardio-
vascular events was provided by the CAFÉ study,54 where, despite
a similar reduction in peripheral systolic BP, a calcium-channel
blocker regimen (amlodipine with perindopril added as required)
was more effective in lowering central systolic BP, and reduced
future cardiovascular events compared to a 𝛽-blocker regimen
(atenolol with bendroflumethiazide-K as required). It should be
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noted that the majority of patients received a combination of
amlodipine with perindopril or atenolol with diuretic (only 26%
on monotherapy) and thus, the difference in cardiovascular events
and central haemodynamics should be related only to treatment
combinations and not to individual drugs. Additionally, antihyper-
tensive drug classes that have more pronounced effects on arterial
stiffness and wave reflection, are the same that cause significant
regression of LV hypertrophy.55
The effects of LCZ696 [angiotensin receptor-neprilysin inhibitor
(ARNI): sacubitril/valsartan] on aortic stiffness were evaluated
in elderly patients with systolic hypertension and pulse pressure
> 60mmHg. At week 12, sacubitril/valsartan reduced central
aortic systolic pressure to a greater extent than olmesartan by
−3.7mmHg. After 52weeks, more patients required add-on anti-
hypertensive therapy with olmesartan (47%) vs. sacubitril/valsartan
(32%).57
Pulse wave velocity and augmentation pressure were significantly
and progressively reduced by renal denervation in patients with
resistant hypertension, especially in hypertensive patients with
more elevated PWV at baseline.58 After renal denervation, actual
PWV measures were lower than the predicted age- and mean
BP-corrected values, suggesting that this intervention might exert
BP-independent effects on arterial stiffness. Additionally, renal
denervation diminished cardiac systolic work load as evident by
shorter ejection duration and reduced systolic BP load after the
procedure, suggesting a substantial effect on VAC.
Similarly, in type 2 diabetics, treatment with glucagon-like
peptide-1 (GLP-1) caused a greater reduction of PWV, central
aortic pressure and wave reflections, and greater improvement of
LV longitudinal deformation and LV twisting-untwisting than met-
formin after 6months of treatment, likely through reduction of
oxidative stress burden as assessed by the reduction of protein
carbonyls and malondialdehyde.51 Indeed, in the above study, the
reduction of malondialdehyde after 6months of GLP-1 treatment
was associated with the respective reduction of PWV which, in
turn, was related with improved LV GLS.
Key points
• Myocardial dysfunction and vascular stiffness are present in
newly diagnosed hypertensives and diabetics.
• Both may contribute to reduced exercise capacity and HF
symptoms.
• There are treatment options that may improve both myocardial
dysfunction and vascular stiffness and thus improve VAC.
Ventricular–arterial coupling
in systemic inflammatory disease
Atherosclerosis, subclinical LV dysfunction, and increased risk
of cardiovascular events characterise rheumatoid arthritis (RA),
systemic lupus erythematosus, ankylosing spondylitis, psoriasis,
gout, and medium- and large-vessel vasculitides.21,59,60 With regard



















































































.. cause an increase in arterial stiffness, leading to increased Ea in
parallel to myocardial stiffening causing an increased Ees.44
In a trial examining 80 patients with RA, the investigators demon-
strated that reduced systemic arterial compliance was related to
reduced LV longitudinal strain and strain rate and abnormal LV
twisting and untwisting velocity as assessed by speckle tracking
echocardiography.59 Similarly, an increased PWV was associated
with reduced LV longitudinal strain in psoriatic patients.60 Further-
more, in a patients with Adamantiades–Behcet’s disease, reduced
aortic distensibility was associated with prolonged deceleration




Anti-inflammatory treatment has been shown to alleviate
ventricular–arterial decoupling. In a double-blind, crossover
study of RA patients, injection of anakinra [a recombinant inter-
leukin (IL)-1 receptor antagonist] resulted in improved systemic
arterial compliance and systemic vascular resistance, improved
E/E’, in parallel with improved indices of LV myocardial deforma-
tion and twisting as assessed by speckle tracking. Interestingly,
the improvement in vascular and myocardial deformation mark-
ers was greater in the group of patients with coexisting CAD
who showed a higher inflammatory burden.60 Administration of
tocilizumab (an IL-6 antagonist) has been shown to reduce PWV,61
improve cardiac function, and reduce LV mass in RA.62 Moreover,
anti-tumour necrosis factor-𝛼 therapy resulted in reduced PWV
after a 3-month follow-up period in patients with inflammatory
arthropathy.63 Additionally, the Physical Activity in RA (PARA)
trial has shown that moderate intensity physical activity resulted
in increased E/A and a trend towards decreased PWV and aug-
mentation index,64 suggesting the reversal of ventricular–arterial
decoupling. Finally, in psoriatic patients, novel biological agents
reduced arterial stiffness, central aortic pressure and wave
reflections, and improved LV longitudinal deformation and LV
twisting-untwisting within 4months, through inflammatory and
oxidative stress burden reduction.65
Key points
• Systemic inflammation concomitantly impairs arterial and
myocardial function.
• Anti-inflammatory treatment improves arterial stiffness in
parallel with myocardial stiffness contributing to reversal of
ventricular–arterial decoupling.
Ventricular–arterial coupling
in valvular heart disease
Aortic stenosis
In patients with aortic stenosis (AS), the left ventricle is often
facing a double load: a valvular load imposed by AS and an
© 2019 The Authors
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Diuretics ↓/↔ ↔ ↔ ↔↓ ↓/↔
𝛽-blockers ↓
Without vasodilating effects ↓ ↓/↔ ↓ ↓ ↔
With vasodilating effects ↓ ↓ ↑ ↑ ↓/↔
𝛼-blockers ↔ ↓ NA
Calcium-channel blockers ↓
Dihydropyridines ↓/↔ ↓ ↓ ↓ ↓/↔
Non-dihydropyridines ↓ ↓ ↓
ACE inhibitors ↓ ↓ ↓↓ ↓↓ ↓
Angiotensin II receptor blockers ↓ ↓ ↓ ↓ ↓/↔
Aldosterone antagonists ↓/↔ ↓ NA
Nitrates ↔ NA ↓↓ ↓↓ NA
ACE, angiotensin-converting enzyme; NA, not available; PWV, pulse wave velocity; ↑, increased; ↓, decreased; ↓↓, marked decrease;↔, no change.
Adapted from Nilsson et al.55 and Boutouyrie et al.56
arterial load caused by a decrease in systemic arterial compliance
(or an increase in systemic vascular resistance) in the context
of existing co-morbidities (e.g. age, smoking, hypertension, dia-
betes) (Figure 6).
Briand et al.66 proposed two practical indexes, systemic arte-
rial compliance (SAC) and valvulo–arterial impedance (Zva) to
assess the effects of aortic wall properties on LV function in
AS. SAC index is the ratio of SV indexed to body surface
area/pulse pressure: SAC≅ SVi/PP. In their study, 40% of patients
with severe AS had markedly reduced arterial compliance (SAC
index < 0.6ml/m2/mmHg) associated with LV dysfunction.66
Valvulo–arterial impedance represents the total haemodynamic
load opposing LV blood ejection into aorta, combining both valvu-
lar and vascular factors, and can be a used as a surrogate marker of
VAC. Zva is obtained non-invasively by calculating the LV pressure
(sum of systolic pressure and the mean pressure gradient obtained
by continuous wave Doppler) divided by SV/m2: Zva≅ LV pres-
sure/SVi (mL/m2/mmHg); thus, it represents the cost in mmHg for
each systemic mL of blood pumped by the left ventricle during
systole. A value > 4.5mmHg/mL/m2 indicates a severely increased
total afterload. Interestingly, Zva was superior to valve area or gra-
dients to predict outcomes.62 Finally both Zva ≥ 4.9mmHg/mL/m2
and LV GLS ≤15.9% independently predicted outcome in asymp-
tomatic moderate to severe AS (aortic valve area ≤ 0.6 cm2/m2)
patients.67
Arterial hypertension and stiffness may also alter VAC and,
thus, accelerate symptoms in AS. In a series of 193 AS patients,68
symptoms occurred earlier in the subset of hypertensive patients,
despite a larger valve area. Moreover, Weisz et al.69 demonstrated
that in patients with moderate to severe AS and preserved
LV ejection fraction, increased carotid and aortic stiffness was
independently associated with elevated LV filling pressures, B-type
natriuretic peptide (BNP) levels, and symptoms.
Ventricular–arterial coupling and Zva have also important




















































. low-gradient AS. These patients are typically elderly, hyperten-
sive, with stiff aorta, elevated arterial afterload despite similar
end-systolic wall stress70 and high Zva. Additionally, in patients with
low-flow, low-gradient AS, Zva was associated with lower aortic
mean gradient.70 Moreover, higher Zva is associated with impaired
longitudinal LV systolic function71 and lower survival.72,73 Zva, like
Ea, has limitations because the complex pulsatile afterload cannot
be lumped in a single parameter. Studies utilizing proper assess-
ments of pulsatile LV afterload in AS are needed.
Aortic regurgitation
Wilson et al.74 found in asymptomatic chronic aortic regurgita-
tion patients that reduced aortic distensibility was related with
increased LV volumes, systolic wall stress and LV mass, and led
more rapidly to aortic valve replacement (AVR). In another study,75
20 patients with non-stenotic biscuspid aortic valve had reduced
aortic elasticity and LV hypertrophy compared to controls.
Interventions to improve
ventricular–arterial coupling
Arterial hypertension and stiffness may alter VAC and, thus,
accelerate symptoms in AS and deteriorate prognosis in patients
with paradoxical low-flow, low-gradient AS. Thus, in patients
with coexisting hypertension, increased markers of arterial stiff-
ness and/or impaired markers of VAC and AS, effective treat-
ment of hypertension with medication which has been also shown
to improve arterial wall properties may delay the occurrence
or reduce the intensity of symptoms. AVR may acutely impact
VAC76 and promote the recovery of mid- and long-term LV
contractility77 and LV GLS.78 However, surgical manipulations of
the aorta may impair perfusion and induce inflammation of the
aortic wall, resulting in reduced aortic elastance and consequently
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Figure 6 In aortic stenosis, increased systemic arterial and aortic valve load act complementarily and competitively, resulting in impaired
left ventricular (LV) elastance; the compensatory mechanisms activated due to tissue hypoperfusion complicate this interaction. Ea, arterial
elastance; Ees, end-systolic elastance; SNS, sympathetic nervous system; SVR, systemic vascular resistance; TAC, total arterial compliance;
VAC, ventricular–arterial coupling.
to ventricular–arterial decoupling.77 The early post-AVR deteri-
oration of aortic elastance is usually followed by a progressive
improvement for up to 1 year.79 In the case of transcatheter aor-
tic valve replacement (TAVR), the aortic root is only minimally
manipulated. The acute decrease of LV pressure overload follow-
ing TAVR80 results in an early reduction of valvular load as well as
improved LV energetics, as demonstrated by VAC normalization.
However, VAC is not always improved post-TAVR. The
post-procedural decrease in afterload results in an abrupt decrease
of LV pressure and contractility (i.e. Ees), with a consequent VAC
disruption.80 Moreover, the relief of valvular obstruction acutely
increases SV and thus in the context of a stiff, non-compliant aorta,
may cause a disproportionate increase of systolic aortic BP, posing
an excessive afterload to the left ventricle. Therefore, arterial load
(i.e. Ea) is increased, negatively affecting LV efficiency81 and blunting
the haemodynamic benefits of TAVR. Thus, the pre-procedural
state of aortic elasticity, myocardial function and VAC may affect
the response to TAVR.
Mitral regurgitation
In chronic severe organic mitral regurgitation, there is a progres-
sive deterioration of LV contractile state (i.e. Ees reduction), which
leads to VAC impairment that is prevented neither by stable Ea, nor
by vasodilator therapy.82 Thus, in chronic mitral regurgitation, the
progressive deterioration of VAC and pump efficiency suggests the
potential progression to clinically overt cardiac dysfunction requir-










































. regurgitation and dilated or ischaemic cardiomyopathy (LV ejec-
tion fraction < 45%),83 there was a significant association between
PWV and functional mitral regurgitation in the ischaemic group.
Furthermore, the preservation of VAC after mitral clip implan-
tation has been associated with an increase in forward SV, despite
a reduced ejection fraction.84
Mitral stenosis
A study85 of patients with severe mitral stenosis undergoing percu-
taneous balloon valvuloplasty and healthy subjects, demonstrated
that mitral stenosis induced an increase in arterial stiffness that was
improved after percutaneous balloon valvuloplasty.
Key points
• VAC assessment possesses diagnostic and prognostic value in
valvular heart disease, over and above stenosis, regurgitation,
or ejection fraction quantification.
• Systemic arterial compliance and Zva can specifically describe
the haemodynamic consequences of AS.
• Zva and LV GLS offer prognostic information in AS even when
asymptomatic.
• Impaired VAC may be the cause of symptoms in AS, despite a
large aortic orifice.
• The pre-procedural state of VAC in the context of increased
aortic stiffness may compromise the beneficial effects of AVR.
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• Deteriorating VAC may suggest cardiac dysfunction in organic
mitral regurgitation.
• Mitral clip implantation in functional mitral regurgitation may
preserve VAC.
Ventricular–arterial coupling
in coronary artery disease
Coronary artery disease shares common pathophysiological pro-
cesses with aortic stiffening.59,86 The severity of CAD has been
associated with impaired markers of arterial stiffness.86 The pres-
ence of significant CAD may negatively affect LV systolic func-
tion particularly in the longitudinal axis. Additionally, an increase
of the arterial load due to increased aortic stiffness may also
affect LV performance.29 Increased PWV was related with reduced
coronary flow reserve in CAD patients even after success-
ful revascularization5 and with elevated N-terminal pro BNP
(NT-proBNP) post-myocardial infarction (Table 2).87 Myocardial
strain imaging (LV GLS < 20%)7,27 has shown to detect subclinical
dysfunction in CAD patients and represents a more sensitive
method of identifying LV performance.21 Increased aortic stiffness
impairs LV function, mainly in the longitudinal axis, through inappro-
priate VAC with mechanisms discussed in detail above (Figure 2).
Thus, non-invasive measurement of VAC can provide comprehen-
sive assessment of LV performance and may also be incremental
to LV ejection fraction in the characterization and clinical manage-
ment of CAD patients. In 891 patients with suspected or known
CAD who had negative stress echocardiography (mean LV ejec-
tion fraction 47%), it was shown that patients with impaired VAC
reserve (measured as the change in Ea/Ees between peak stress
and rest) had increased rates of all-cause mortality, compared with
patients with more preserved VAC reserve.88 Additionally, among
41 patients with ischaemic cardiomyopathy (LV ejection fraction
47±13%), those with an Ea/Ees ratio < 1.47 had better survival
than patients with higher (more impaired) Ea/Ees ratios (≥ 1.47).89
Furthermore, increased arterial wave reflections predict severe
cardiovascular events in patients undergoing percutaneous coro-
nary interventions, and various markers of arterial stiffness have
been associated with adverse outcome in CAD.86
Key points
• There is evidence suggesting the use of LV GLS, VAC assess-




Heart failure with reduced ejection
fraction
In the context of HF with reduced ejection fraction (HFrEF),



















































































.. Ees) decreases, systemic tissue hypoperfusion occurs. The
renin–angiotensin–aldosterone system and the sympathetic
nervous system are consequently over-activated, in an attempt
to increase intravascular volume and arterial load, and counterbal-
ance the impaired systemic perfusion; thus, Ea is increased. The
increased Ea along with the direct cardiotoxicity of sympathetic
over-activation and the increased myocardial oxygen demands
of hyper-dynamic circulation create a vicious circle predisposing
to further worsening of cardiovascular function and syndrome
progression (Figure 7).
Indeed, in a cohort of 466 patients with HFrEF, VAC (Ea/Ees)
was strongly associated with New York Heart Association (NYHA)
functional class, increase in natriuretic peptides, and adverse clinical
outcomes.90
A reduced GLS91 and/or a small GLS increase after stress
echocardiography (< 19%)92 have been demonstrated to be inde-
pendent prognosticators of mortality in HFrEF. Furthermore,
markers of arterial stiffness (pulse pressure, PWV, central systolic
BP) have been found to be independent predictors of outcome in
HFrEF.93
Interventions to improve ventricular–arterial coupling
in heart failure with reduced ejection fraction
Ventricular–arterial coupling may also be useful to assess response
to various therapeutic approaches in chronic HF. Table 4 summa-
rizes various therapeutic strategies having beneficial effects on VAC
in HFrEF.53,57,59,65,94–107
In a prospective clinical trial, 38 patients with HFrEF underwent
aggressive titration of vasoactive HF medications (ACE inhibitors,
carvedilol, nitrates, MRAs) with assessment of central aortic
waveforms.94 Clinical response to treatment was assessed using the
6-min walk test, which increased in 25 patients and decreased or
remained unchanged in 13. Patients with clinical improvement after
therapy displayed higher baseline aortic pressure wave pulsatility
(central pulse pressure, reflected pressure wave, and reservoir
pressure) than patients without improvement. After treatment,
aortic pressure pulsatility decreased only in patients with functional
improvement. These differences in arterial load at baseline and on
therapy were not apparent from conventional brachial artery cuff
pressure assessments. Thus, central aortic waveform analysis may
allow an individualized treatment regimen for patients with HFrEF.
In a study including 877 elderly patients with HF (age ≥ 65
years, NYHA class ≥ II, LV ejection fraction ≤ 45 %), treated with
𝛽-blockers, underwent Doppler echocardiography before and after
12weeks of treatment.95 VAC, as assessed by Ea/Ees, improved
after treatment. Ea decreased from 2.73± 1.16 to 2.40±1.01,
resulting in a near-optimization of VAC ratio [from 1.70± 1.05
(1.46) to 1.50± 0.94 (1.29)]. A similar VAC response was evident
in patients with ischaemic and non-ischaemic HF and was related
with lower degree of HF functional class (NYHA) after 𝛽-blocker
administration. The strongest predictor of VAC alteration was
the LV ejection fraction increase. Thus, the beneficial effect of
𝛽-blockers in elderly HF patients may have been achieved, at least
partly, by VAC optimization, associated with cardiac contractility
improvement.
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Figure 7 In the heart failure with reduced ejection fraction model of ventricular–arterial decoupling, a primary reduction of left ventricular
elastance results in a compensatory increase of systemic arterial elastance (Ea); their interaction creates a vicious circle. CO, cardiac output;
DCM, dilated cardiomyopathy; HR, heart rate; MI, myocardial infarction; RAAS, renin–angiotensin–aldosterone system; SNS, sympathetic
nervous system; SVR, systemic vascular resistance, SV, stroke volume; TAC, total arterial compliance; VAC, ventricular–arterial coupling.
Eplerenone improves endothelial function and vascular compli-
ance in HFrEF patients, while having beneficial effects on their
exercise capacity, quality of life, and prognosis. Moreover, this agent
exerts anti-fibrotic action, alleviating cardiac remodelling and LV
stiffness.96
Ivabradine (If inhibition) lowers heart rate and improves cardiac
function and prognosis in HFrEF.108 Ivabradine altered haemody-
namics in the murine aorta by increasing the magnitude of shear
stress.97 This change was accompanied by endothelial nitric oxide
synthase induction and vascular cell adhesion molecule-1 suppres-
sion. Thus, ivabradine creates local mechanical conditions that trig-
ger protective anti-inflammatory responses in the arterial wall.97
Moreover, IL-1 inhibition by anakinra has been shown to improve
exercise capacity in HFrEF patients after 12 weeks of treatment98
as well as to improve arterial load, coronary flow reserve and LV
myocardial deformation in CAD patients with coexisting RA.61
Steendijk et al.99 described the VAC and mechanical efficiency
improvement that is induced by cardiac resynchronization ther-
apy in relation with the observed improvements in clinical and
functional status. Another study100 highlighted value of myocar-
dial strain–BP loops (reflecting the VAC status) to calculate
myocardial work index non-invasively and thus to predict the
long-term clinical response to cardiac resynchronization therapy
(Figure 5).
Lastly, cardiopulmonary rehabilitation on top of optimal treat-
ment is associated with VAC and LV mechanical efficiency opti-
mization in HFrEF patients with systolic HF. This beneficial effect










































. in arterial compliance, peripheral resistance, wave reflections,
skeletal muscle oxidative function, and arterial–venous oxygen
difference.101
Heart failure with preserved ejection
fraction
Heart failure with preserved ejection fraction is a common
condition in the elderly and is associated with a high bur-
den of co-existing co-morbidities (especially arterial hypertension
and diabetes).44 Arterial stiffening contributes to the pathophysi-
ology of HFpEF via arterial–ventricular mismatching, particularly
with exertion, afterload-induced diastolic dysfunction, and suben-
docardial ischaemia.9,20,22 Additionally, in acute hypertensive HF,
abnormal VAC can lead to acute pulmonary congestion. In HFpEF,
impairment of VAC is related to inflammatory and mechanical over-
load caused by arterial hypertension and other co-morbidities;
thus abnormal VAC may be considered a primary mechanism for
the clinical deterioration of HF (Figure 8). As LV and arterial elas-
tances increase in parallel, the classic Ea/Ees ratio is insensitive to
abnormal VAC states in HFpEF. Thus, either each component of
the ratio should be examined separately or novel markers of VAC
assessment, as described above, should be utilized.Weber4 demon-
strated that HFpEF is characterized by increased arterial stiffness
and wave reflections, which increase the late systolic pulsatile load
of the left ventricle. Among the novel markers proposed to assess
the ventricular–arterial interaction, an increased PWV, a marker
of arterial stiffness, is a major determinant of abnormal LV GLS, a
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Table 4 Main effects of medical therapy on ventricular–arterial coupling in chronic and acute heart failure patients
Therapeutic approach Main effect
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
HFrEF
Vasodilators94 Reduction of central pressures and afterload
𝛽-blockers95 Improvement of ventricular–arterial interaction
MRAs96 Reduction of cardiac fibrosis and improvement of endothelial/vascular function
Ivabradine97 Vascular stiffness alleviation
Anakinra (IL-1 receptor antagonist)98 Reduction of inflammation and oxidative stress and improvement of exercise capacity,
arterial load and LV myocardial deformation
CRT99,100 Improvement of VAC and cardiac remodelling
Exercise training101 Improvement of arterial compliance and LV mechanical efficiency
HFpEF
Sodium restriction102 Improvement of arterial elastance and VAC
Anti-hypertensive therapy (RAAS inhibitors)53,103 Improvement of cardiac and vascular stiffness
Ivabradine97 Improvement of vascular stiffness, anti-fibrotic properties
Anakinra (IL-1 receptor antagonist)59
Ustekinumab (IL-12 receptor antagonist)65
Reduction of inflammation and oxidative stress and improvement of vascular function,
coronary flow reserve and LV myocardial deformation
ARNI (sacubitril/valsartan)57 Reduction of central pressures and afterload
Acute heart failure
IV vasodilators (IV nitrates)103 Reduction of preload and afterload/improvement of filling pressures
Serelaxin104–106 Reduction of afterload, organ protection, improvement of vascular function
Levosimendan107 Vasodilatation with positive lusitropic properties, improvement of right
ventricular–pulmonary arterial coupling
ARNI, angiotensin receptor-neprilysin inhibitor; CRT, cardiac resynchronization therapy; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with
reduced ejection fraction; IL, interleukin; IV, intravenous; LV, left ventricular; MRA, mineralocorticoid receptor antagonist; RAAS, renin–angiotensin–aldosterone system;
VAC, ventricular–arterial coupling.
sensitive marker of LV dysfunction, and is associated with reduced
aerobic exercise capacity in hypertensive heart disease48 while a
reduced LV GLS (< 16%), has been shown to predict mortality fol-
lowing hospitalization for HFpEF.102
Interventions to improve ventricular–arterial coupling
in heart failure with preserved ejection fraction
Table 4 also describes therapeutic interventions that may restore
VAC in HFpEF. Furthermore, in hypertensives with HFpEF, a
sodium-restricted diet was associated with favourable changes in
LV diastolic function, Ea, and VAC.109
Nitric oxide is an important regulator of muscular artery tone
and the magnitude of wave reflection. Orally administered inor-
ganic nitrates (which are direct precursors of nitric oxide via the
nitrate–nitrite–nitric oxide pathway) have been shown to reduce
wave reflections and increase exercise capacity in HFpEF.110 How-
ever, the recent INDIE-HFpEF111 trial failed to demonstrate any
improvement in peak oxygen uptake (VO2) with use of inhaled
sodium nitrite with short half-life (∼35–40min) and pronounced
drug fluctuations, which are an important barrier to its efficacy. The
negative results of this and previous studies112 highlight the need
for more studies that use other outcome measures (besides VO2)
to evaluate the efficacy of nitric oxide donor agents in patients with
HFpEF (e.g. cardiac function markers, biomarkers, and/or hospi-
talizations for HF). However, these results may also indicate that
the use of inhaled sodium nitrite with its short half-life in not an









































. nitrite, orally administered inorganic nitrate has a longer half-life
(∼5–8 h) and does not seem to commonly induce hypotension
with single or continued administration.113,114
In a diabetic HFpEF mouse model, ivabradine administra-
tion improved vascular stiffness, LV contractility, and diastolic
function.115 Additionally, short-term treatment with ivabradine
increased exercise capacity, due to improved LV filling pressure
response to exercise116 in humans, though others had failed to
demonstrate meaningful improvement in VO2.
117
Recently, the novel combination ARNI (sacubitril/valsartan)
led to a significant improvement of central aortic and brachial
pressures in elderly patients with systolic hypertension,57 while
effectively reduced NT-proBNP and circulating pro-fibrotic mark-
ers in HFpEF patients in the PARAMOUNT trial, suggesting bene-
ficial effects of the drug on VAC.118 PARAGON-HF is an ongoing
trial that investigates the effect of ARNI on major cardiovascular
outcomes in HFpEF.
In acute hypertensive HF, intravenous nitrates103 or the new
agent serelaxin effectively reduced afterload, as well as pul-
monary congestion by way of vascular stiffness alleviation and VAC
optimization119 (Table 1). Although serelaxin improved 180-day
mortality in phase II RELAX-AHF,104,105 this benefit on adverse out-
come was not confirmed in the following phase III RELAX-AHF-2
study in a larger patient cohort.106 Thus, the neutral results of
trials such as NEAT-HFpEF (mean age 69 years, 57% women,
objective evidence of HF, LV ejection fraction > 50% and reduced
self-reported activity levels), INDIE-HFpEF [mean age 68 years,
© 2019 The Authors
European Journal of Heart Failure © 2019 European Society of Cardiology
420 I. Ikonomidis et al.
Figure 8 In the heart failure with preserved ejection fraction model of ventricular–arterial decoupling, cardiovascular co-morbidities and risk
factors induce pro-inflammatory and pro-fibrotic cascades that concomitantly impair left ventricular and systemic arterial elastance; further
damage results from their interaction. CH, concentric hypertrophy; CRP, C-reactive protein; DM, diabetes mellitus; HTN, hypertension; IL-6,
interleukin-6; LV CR, left ventricular contractile reserve; NO, nitric oxide; PKG, protein kinase-G; SVR, systemic vascular resistance; TAC,
total arterial compliance; TGF-𝛽, transforming growth factor-𝛽; TNF-a, tumour necrosis factor alpha; VCAM, vascular cell adhesion molecule.
68% women, objective evidence of HF, LV ejection fraction
> 50% and reduced exercise capacity (peak VO2 ≤ 75%)], and
RELAX-AHF-2 (mean age 73 years, 40% women, hospitalized for
acute decompensated HF, mean LV ejection fraction of 40%)
on cardiovascular risk reduction106,111,112 have raised questions
regarding the utility of targeting afterload reduction, the timing of
intervention,104 and the drug of choice to improve vascular function
and, thus, outcomes in HFpEF or acute decompensated HF.
In patients with right-sided HF due to LV dysfunction or primary
pulmonary hypertension, the inodilator levosimendan increases
cardiac output by restoring right ventricular–pulmonary arterial
coupling and decreasing pulmonary vascular resistance.107 Finally,
treatment with IL-1 or IL-12 inhibitors has shown beneficial effects
on arterial load, myocardial deformation and NT-proBNP, suggest-
ing an improvement of VAC in inflammatory disease.59,65
Although endurance exercise training improves exercise capac-
ity in older patients with HFpEF, it does not appear to have a
significant effect on markers of endothelial function and arterial
stiffness.120,121
Key points
• Abnormal VAC is implicated in the pathophysiology of left and
right HF clinical deterioration.
• Different patterns of abnormal VAC are recognized in HFrEF
vs. HFpEF.
• Restoration of VAC may be a new therapeutic target in HF and
pulmonary hypertension.
• More mechanistic and VAC-guided therapy clinical trials are















































The right ventricle undergoes adaptive changes in response
to increased pulmonary artery pressures. Initially, the compen-
satory increased contractility and hypertrophy suffice to match
the respective right ventricular afterload. Eventually, however,
ventricular–arterial decoupling ensues with an increased Ea/Ees
ratio.122 Right ventricular–pulmonary arterial coupling may inde-
pendently predict transplantation-free survival of patients with
pulmonary hypertension.123 Although data regarding humans are
limited, a number of pulmonary hypertension pharmacotherapies
(e.g. drugs inducing pulmonary vasodilatation) have demonstrated
beneficial effects on right ventricular–arterial coupling in animal
models.124
Key points
• Abnormal VAC is involved in the pathophysiology of right HF
in pulmonary hypertension. Studies should further examine
whether improvement of VAC by treatment will also improve
symptoms and prognosis in pulmonary hypertension.
Conclusion
Fibrosis, inflammation and oxidative stress are common bio-
chemical pathways linking impaired ventricular–arterial function.
Increased arterial stiffness/wave reflections are associated with var-
ious maladaptive structural and functional LV changes, contributing
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to the development of HF. VAC assessment possesses independent
diagnostic and prognostic value in cardiac disease and may be used
to refine risk stratification. Traditionally, VAC is assessed by the
non-invasive measurement of the Ea/Ees ratio. With disease pro-
gression, both Ea and Ees may become abnormal and the Ea/Ees
ratio may approximate normal values (∼1). Therefore, the mea-
surement of each component of this ratio or of novel, more
sensitive markers of myocardial (e.g. GLS) and arterial function
(e.g. PWV) may describe and quantify VAC. Treatment guided
to improve VAC through improvement of both or each one
of its components (Ea, arterial stiffness, central BP and/or myocar-
dial elastance and deformation) may delay the progression to HF
and possibly improve prognosis. More mechanistic and VAC-guided
large-scale clinical trials are needed in this field.
Gaps in evidence
There are still several unanswered questions related to the study
of VAC in cardiac disease. The optimal marker that will be easy
to use in daily clinical practice to assess VAC and myocardial
work efficiency and to monitor the effects of treatment is not yet
established.
The effects of pre-procedural VAC on valve interventions such
as TAVR and mitral clip or cardiac resynchronization therapy device
implantation and its utility to assist patient selection or assess
response to intervention have not been fully defined.
The effects of nitric oxide donors on vascular and myocar-
dial function using new endpoints besides exercise capacity (e.g.
myocardial function markers, hospitalizations, mortality), as well as
dose or duration of this treatment should be examined.
The appropriate type, dose and duration of anti-inflammatory
treatment to improve VAC in systemic inflammatory diseases,
CAD, and HF, as well as the association of VAC improvement with
improved functional status and reduced cardiovascular outcomes
are not clarified. Finally, the drug, dosage, duration and, more
importantly, the timing of treatment targeting afterload reduction
especially in acute HF in order to have a beneficial effect on adverse
cardiovascular events are not known.
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